G1 Therapeutics Inc
(FRA:G1H)
€
6.345
0 (0%)
Market Cap: 339.15 Mil
Enterprise Value: 327.68 Mil
PE Ratio: 0
PB Ratio: 15.31
GF Score: 31/100 G1 Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 11, 2021 / 07:00PM GMT
Release Date Price:
€25.17
(+2.94%)
Yige Guo
Guggenheim Securities, LLC, Research Division - Associate
All right. Good afternoon, everyone. And welcome to Guggenheim Healthcare Talks 2021 Oncology Days. My name is Yige Guo and I'm an associate research analyst here at Guggenheim working with Michael Schmidt.
Our next fireside chat is with G1 Therapeutics. I'm joined by Jack Bailey, CEO; Soma Gupta, Chief Commercial Officer; Raj Malik, Chief Medical Officer. Welcome, Jack, Soma and Raj.
John E. Bailey
G1 Therapeutics, Inc. - CEO, President & Director
Thank you, Yige.
Questions & Answers
Yige Guo;John E. Bailey
Guggenheim Securities, LLC, Research Division - Associate;G1 Therapeutics, Inc. - CEO, President & Director
Now in the interest of time, I will directly jump into questions. Probably to start with a high-level question. Jack, as the new CEO, what is your vision for chemotherapeutics? And how do you plan on balancing commercialization of trilaciclib with future pipeline investment?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot